Taurolite ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1

2. Amyotrophic lateral sclerosis


Clinical trials : 624 Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-002722-22-GB
(EUCTR)
20/05/201928/02/2019Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS) - TUDCA-ALS amyotrophic lateral sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Taurolite
Product Name: Taurolite
INN or Proposed INN: Tauroursodeoxycholic acid
IRCCS ISTITUTO CLINICO HUMANITASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
440Phase 3Netherlands;United Kingdom